Pinpointing couples requiring chromosome analysis

Article

It's more than just the number of miscarriages that determines the likelihood of structural chromosome abnormalities, say researchers from the Netherlands. In couples who are trying to conceive and who have had two or more miscarriages, young maternal age at the time of a second miscarriage, a history of three or more miscarriages, and a history of two or more miscarriages in siblings or parents of either partner make the couple more likely to be carriers of such anomalies, according to the results of a nested case–control study.

It's more than just the number of miscarriages that determines the likelihood of structural chromosome abnormalities, say researchers from the Netherlands. In couples who are trying to conceive and who have had two or more miscarriages, young maternal age at the time of a second miscarriage, a history of three or more miscarriages, and a history of two or more miscarriages in siblings or parents of either partner make the couple more likely to be carriers of such anomalies, according to the results of a nested case–control study.

The study, involving 279 carrier couples and 428 non-carrier control couples, found that maternal age at second miscarriage was the most influential factor.

The authors calculated that finding an effective way to narrow the number of couples who are offered chromosome analysis could reduce the number performed by 18%, thus significantly lowering health-care costs.

Recent Videos
Empowering women to take charge of their health | Image Credit: © piecesofi.com - © piecesofi.com - stock.adobe.com.
Supporting women through menopause with knowledge and care | Image Credit: © SHOTPRIME STUDIO - © SHOTPRIME STUDIO - stock.adobe.com.
How fezolinetant revolutionizes non-hormonal menopause therapy | Image Credit: imsociety.org
Gulf War exposures linked to early menopause in women veterans | Image Credit: linkedin.com.
Vanessa Muñiz discusses benefits of clinical hypnosis against hot flashes | Image Credit: mindbodymedicine.artsandsciences.baylor.edu
Elinzanetant displays positive phase 3 safety and efficacy data against VMS | Image Credit: © toeytoey - © toeytoey - stock.adobe.com.
Lauren Streicher, MD
© 2024 MJH Life Sciences

All rights reserved.